| DC Field | Value | Language |
|---|
| dc.contributor.author | Pushkin, A. A. | - |
| dc.contributor.author | Burda, Yu. E. | - |
| dc.contributor.author | Sevastyanov, A. A. | - |
| dc.contributor.author | Kulikovskiy, V. F. | - |
| dc.contributor.author | Burda, S. Yu. | - |
| dc.date.accessioned | 2022-04-26T12:12:47Z | - |
| dc.date.available | 2022-04-26T12:12:47Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | Renal cell carcinoma drug and cell therapy: today and tomorrow / Pushkin, A. A. [et al.] // Research result: pharmacology and clinical pharmacology. - 2018. - Vol. 4, № 1.- P. 17-25. - Doi: 10.3897/rrpharmacology 4.25251. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46384 | - |
| dc.description.abstract | The paper also looks at clinically applicable targeted immune drugs and the principle of their effect on tumorous cells. Besides, modern clinical studies of cell drugs have been considered | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | urology | ru |
| dc.subject | urological pathology | ru |
| dc.subject | renal cell carcinoma | ru |
| dc.subject | renal cancer | ru |
| dc.subject | targeted therapy | ru |
| dc.subject | immunotherapy | ru |
| dc.subject | cancer cell therapy | ru |
| dc.subject | immune system | ru |
| dc.title | Renal cell carcinoma drug and cell therapy: today and tomorrow | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 4, № 1
|
